Introduction: The majority of the world's population is chronically deficient in vitamin D. ergocalciferol (D2) and cholecalciferol (D3) are the two forms of vitamin D. (D3). In terms of potency, vitamin D2 in the form of ergocalciferol (D2) is superior to vitamin D3 (D3). It is possible to get ergocalciferol from herbal sources, but cholecalciferol is produced in the body by being exposed to ultraviolet B radiation on the skin (UVB). Vitamin D is made from ergocalciferol, which is a precursor.

Objectives: Whether or if vitamin D deficiency is linked to ischemic cardiomyopathy is the major purpose of this study (heart failure).

Material and methods: From August to December 2021, researchers from Queen Mary University performed a cross-sectional study. Participants were required to undergo physical exams, blood tests, and echocardiographic evaluations as part of the research procedure. Venous blood samples were obtained the next morning after subjects had fasted the previous night (10 to 12 hours). After that, the serum was centrifuged and sent to the laboratory for biochemical examination as quickly as feasible.

Results: A total of 50 persons participated in this research, which depends on data supplied by patients. There were no changes in age, gender, BMI, or sun exposure between the two groups of subjects. In ICMP patients, calcium levels were the only significant difference from those in the control group. Other biochemical indicators did not vary substantially across subjects. As compared to the general population, persons with ICMP had notably reduced mean 25(OH) D3 levels (14.5-7.4 ng/ml as opposed to 28.2-12.2; P = 0.001), but significantly higher PTH and NT-proBNP concentrations. Conclusion: Vitamin D levels were revealed to be lower in ICMP patients than in controls, and it was proved that this shortfall had a major effect on heart function.

Keywords: Vit-D, Patients, Cardiac Functions, Cardiomyopathy